KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Cash & Equivalents (2016 - 2025)

Acadia Pharmaceuticals has reported Cash & Equivalents over the past 16 years, most recently at $177.7 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $177.7 million for Q4 2025, down 44.4% from a year ago — trailing twelve months through Dec 2025 was $177.7 million (down 44.4% YoY), and the annual figure for FY2025 was $177.7 million, down 44.4%.
  • Cash & Equivalents for Q4 2025 was $177.7 million at Acadia Pharmaceuticals, down from $258.0 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for ACAD hit a ceiling of $319.6 million in Q4 2024 and a floor of $94.6 million in Q3 2021.
  • Median Cash & Equivalents over the past 5 years was $183.2 million (2023), compared with a mean of $193.9 million.
  • Peak annual rise in Cash & Equivalents hit 75.94% in 2021, while the deepest fall reached 79.08% in 2021.
  • Acadia Pharmaceuticals' Cash & Equivalents stood at $147.4 million in 2021, then dropped by 22.1% to $114.8 million in 2022, then soared by 64.27% to $188.7 million in 2023, then soared by 69.4% to $319.6 million in 2024, then tumbled by 44.4% to $177.7 million in 2025.
  • The last three reported values for Cash & Equivalents were $177.7 million (Q4 2025), $258.0 million (Q3 2025), and $253.6 million (Q2 2025) per Business Quant data.